YOU ARE ABOUT TO EXIT A GLOBAL HEMANEXT ONE PRODUCT WEBSITE FOR THE US HEMANEXT CORPORATE WEBSITE
Please be aware that the website you have requested is intended for the residents of the United States. The Hemanext One® System has not been cleared, approved, or otherwise authorized by the US Food & Drug Administration for commercial distribution in the United States.
WITH DO YOU WISH TO CONTINUE AND EXIT THIS WEBSITE?
Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food and Drug Administration (FDA) LEXINGTON, Mass., September 21, 2023, –Hemanext Inc., a leading innovator in blood processing, storage, and...
LEXINGTON, Mass., September 18, 2023, – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, marks a significant turning point in its history as the company announces the retirement of its founder, Martin Cannon. Simultaneously,...
LEXINGTON, Mass., September 7, 2022, PR NEWSWIRE – Hemanext Inc., a leading innovator in blood processing, storage, and transfusion technology, today announced that it has initiated the rollout of its Hemanext ONE® RBC (Red Blood Cell) Processing and Storage System in...
Hemanext signs agreements with leading European healthcare distributors to provide hospitals and clinicians with Hemanext ONE® system, marking the initiation of commercialization activities after CE Mark certification LEXINGTON, Mass., August 23, 2022, PR NEWSWIRE –...
Research shows that hypoxic storage preserves faster oxygen unloading from red blood cells compared to standard conditions.1 PRESS RELEASE – LEXINGTON, Mass., August 5, 2022 – (PR.com) – Hemanext Inc. Hypoxic storage preserves faster oxygen unloading from red blood...
